NEW YORK (GenomeWeb News) – Bruker today announced preliminary second-quarter revenues of $420 million, falling short of analyst estimates of $434.5 million.

The company posted revenues of $401.2 million a year ago. Bruker is scheduled to report its second-quarter earnings on July 31.

Bruker added that EPS for the second quarter is expected to be in the range of $.05 and $.07, while adjusted EPS is expected to fall between $.11 and $.13, which would also miss a consensus Wall Street estimate of $.21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.